Des arachides moins allergènes grâce au plasma froid – Le Devoir
The intersection of food science and allergy prevention has yielded a promising new approach: using cold plasma technology to reduce the allergenicity of peanuts. This innovative method, which treats peanut proteins with ionized gas at low temperatures, aims to modify the molecular structure of allergens without compromising nutritional value or taste. Early research suggests this could significantly lower the risk of severe allergic reactions, offering a potential breakthrough for millions affected by peanut allergies worldwide.
Peanut allergy remains one of the most common and persistent food allergies, particularly in children. Unlike some allergies that may be outgrown, peanut allergy often lasts a lifetime and is responsible for a disproportionate number of food-induced anaphylaxis cases. Current management relies heavily on strict avoidance and emergency epinephrine apply, placing a significant burden on individuals, families, and healthcare systems. The search for safe, effective ways to reduce allergenicity has intensified in recent years, with approaches ranging from oral immunotherapy to genetic modification and now, non-thermal plasma treatment.
Cold plasma, also known as non-thermal plasma, is a partially ionized gas generated at near-room temperatures. When applied to food proteins, it can induce subtle chemical changes—such as oxidation, crosslinking, or fragmentation—that alter IgE-binding epitopes, the specific parts of allergens recognized by the immune system. Studies have shown that this process can reduce the immunoreactivity of major peanut allergens like Ara h 1, Ara h 2, and Ara h 3 without significantly affecting the protein’s functional properties, such as solubility or emulsification capacity.
Research conducted by food scientists and allergists has demonstrated that cold plasma treatment can decrease peanut allergen levels by up to 90% in laboratory settings. One study published in a peer-reviewed journal found that after plasma exposure, the IgE binding capacity of peanut extracts was markedly reduced, indicating lower allergenic potential. Importantly, sensory evaluations have shown minimal impact on flavor, aroma, or texture, addressing a key concern with food modification technologies.
The appeal of cold plasma lies in its status as a non-chemical, non-thermal process. Unlike irradiation or chemical treatments, it does not leave residues, nor does it require high heat that could degrade nutrients or create undesirable byproducts. It is also relatively energy-efficient and can be integrated into existing food processing lines, making it a scalable option for industrial application. Regulatory bodies in several countries have begun evaluating plasma-treated foods for safety, with early assessments indicating no toxicological concerns.
While the technology shows promise, experts caution that reduced allergenicity does not equate to zero risk. Plasma-treated peanuts would not be safe for individuals with severe peanut allergies to consume freely, but they could lower the threshold for reactions, potentially protecting against accidental exposures. This aligns with the broader goal of allergy mitigation: creating safer food environments rather than expecting complete tolerance. Such products might be particularly useful in shared settings like schools, airlines, or food service establishments where cross-contamination is a concern.
Ongoing research is focused on optimizing treatment parameters—such as plasma power, exposure time, and gas composition—to maximize allergen reduction while preserving quality. Scientists are also investigating whether the modified proteins retain their ability to induce long-term immune tolerance, a key factor if such peanuts were ever considered for use in immunotherapy protocols. Collaborative efforts between food engineers, immunologists, and clinical allergists are essential to bridge the gap between laboratory findings and real-world application.
Public perception and regulatory approval will play critical roles in determining whether cold plasma-treated peanuts reach consumers. Transparent labeling and clear communication about the technology’s purpose and limitations will be essential to build trust. As with any novel food intervention, rigorous safety testing and ethical consideration must precede widespread use. Nonetheless, the approach represents a compelling example of how physics-based technologies can be harnessed to address pressing public health challenges.
For individuals managing peanut allergies, staying informed about emerging risk-reduction strategies is vital. While avoidance remains the cornerstone of care, advances like cold plasma treatment offer hope for a future where accidental exposure carries less danger. Continued investment in interdisciplinary research, coupled with thoughtful regulation and public engagement, will be key to translating scientific innovation into meaningful protection for those living with food allergies.
As research progresses, the next checkpoint will be the publication of clinical or pilot trial data assessing the safety and efficacy of plasma-treated peanuts in controlled human studies. Until then, individuals are encouraged to consult with allergists or immunologists for personalized guidance on managing peanut allergy.
We welcome your thoughts and experiences. Share this article to help spread accurate, science-based information about food allergy innovation.